Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors
Clinical trial NCT02836795 · COMPLETED
Trial details
- NCT number
- NCT02836795
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-04-01
- Primary completion
- 2018-09-01
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.